Das Produkt wurde korrekt in den Warenkorb gelegt.

discount label
Ac-VFAQ-OH
3D-Ansicht

Biosynth logo

Ac-VFAQ-OH

Ref. 3D-PP45352

Unbestimmte GrößeNachfragen
Voraussichtliche Lieferung in Vereinigte Staaten, am Dienstag 10. Dezember 2024

Produktinformation

Name:
Ac-VFAQ-OH
Synonyme:
  • Ac-Val-Phe-Ala-Gln-OH
Beschreibung:

Peptide Ac-VFAQ-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using Ac-VFAQ-OH include the following: Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia Z Awan , A Baass , J Genest - Clinical chemistry, 2014 - academic.oup.comhttps://academic.oup.com/clinchem/article-abstract/60/11/1380/5621718 Potential opportunity in the development of new therapeutic agents based on endogenous and exogenous inhibitors of the proprotein convertases Y Bontemps, N Scamuffa, F Calvo - Medicinal Research , 2007 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/med.20072 Inhibitory feature of the proprotein convertases prosegments Y Bontemps, M Lapierre, G Siegfried , F Calvo - Medicinal , 2008 - researchgate.nethttps://www.researchgate.net/profile/Marion-Lapierre/publication/5516648_Inhibitory_Feature_of_the_Proprotein_Convertases_Prosegments/links/5406f58c0cf2bba34c1e7d16/Inhibitory-Feature-of-the-Proprotein-Convertases-Prosegments.pdf Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? Y Banerjee , RD Santos , K Al-Rasadi , M Rizzo - Atherosclerosis, 2016 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0021915016300612 GALNT2 regulates ANGPTL3 cleavage in cells and in vivo of mice X Li, Y Zhang, M Zhang, Y Wang - Scientific Reports, 2020 - nature.comhttps://www.nature.com/articles/s41598-020-73388-3 The Multifaceted Furin-like Proprotein Convertases: Defining their in vivo roles in physiological models WJ Kim - 2016 - search.proquest.comhttps://search.proquest.com/openview/6ac57923b27f474d81d6a08b274fa34c/1?pq-origsite=gscholar&cbl=18750&diss=y Development of enhanced furin inhibitors with reduced toxicity as potential broad spectrum antiviral drugs Entwicklung optimierter Furinhemmstoffe mit reduzierter W mit breitem Wirkungsspektrum - archiv.ub.uni-marburg.dehttps://archiv.ub.uni-marburg.de/diss/z2021/0510 Relative expression of proprotein convertases in rat ovaries during pregnancy SCM Kwok, D Chakraborty , MJ Soares - Journal of Ovarian , 2013 - Springerhttps://link.springer.com/article/10.1186/1757-2215-6-91 Proprotein convertase inhibitory activities of flavonoids isolated from Oroxylum indicum S Majumdar, BC Mohanta - Current medicinal , 2010 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cmc/2010/00000017/00000019/art00004 LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation RH Alghamdi, P O'Reilly, C Lu, J Gomes - European journal of , 2015 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0223523415000422 The biology and therapeutic targeting of the proprotein convertases NG Seidah , A Prat - Nature reviews Drug discovery, 2012 - nature.comhttps://www.nature.com/articles/nrd3699 The multifaceted biology of PCSK9 NG Seidah , A Prat - Endocrine Reviews, 2022 - academic.oup.comhttps://academic.oup.com/edrv/article-abstract/43/3/558/6385885 The proprotein convertases, 20 years later NG Seidah - Proprotein Convertases, 2011 - Springerhttps://link.springer.com/protocol/10.1007/978-1-61779-204-5_3 Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells MC McNutt, TA Lagace, JD Horton - Journal of Biological Chemistry, 2007 - ASBMBhttps://www.jbc.org/article/S0021-9258(20)54765-0/abstract The role of proprotein convertases in the regulation of the function of immune cells in the oncoimmune response M Rose , M Duhamel , F Rodet, M Salzet - Frontiers in Immunology, 2021 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.667850/full Mutation in the PCSK9 gene in Omani Arab subjects with autosomal dominant hypercholesterolemia and its effect on PCSK9 protein structure K Al-Waili , WAM Al-Zidi, AR Al-Abri - Oman medical , 2013 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3562979/ Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell J Mayne , T Dewpura, A Raymond, L Bernier - Clinical , 2011 - academic.oup.comhttps://academic.oup.com/clinchem/article-abstract/57/10/1415/5621266 Molecular basis for LDL receptor recognition by PCSK9 HJ Kwon, TA Lagace, MC McNutt - Proceedings of the , 2008 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.0712064105 Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the brain and relevance for neuropsychiatric disorders EM O'Connell, FW Lohoff - Frontiers in neuroscience, 2020 - frontiersin.orghttps://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00609 Regions of conformational flexibility in the proprotein convertase PCSK9 and design of antagonists for LDL cholesterol lowering D Kirchhofer, DJ Burdick, NJ Skelton - Biochemical Society , 2020 - portlandpress.comhttps://portlandpress.com/biochemsoctrans/article-abstract/48/4/1323/226077 Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia D Cunningham , DE Danley, KF Geoghegan - Nature structural & , 2007 - nature.comhttps://www.nature.com/articles/nsmb1235 Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels-experimental and clinical approaches with lipid-lowering agents C Macchi, M Banach , A Corsini - European Journal of , 2019 - academic.oup.comhttps://academic.oup.com/eurjpc/article-abstract/26/9/930/5926000 Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer A Bhattacharya , A Chowdhury, K Chaudhury - et Biophysica Acta (BBA , 2021 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0304419X21000780 C2-Symmetric azobenzene-amino acid conjugates and their inhibition of Subtilisin Kexin Isozyme-1 A Basak, D Mitra, AK Das , D Mohottalage - Bioorganic & medicinal , 2010 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0960894X10005718

Hinweis:
Unsere Produkte sind nur für Laborzwecke. Für jede andere Verwendung, bitte melden sie sich bei uns.
Marke:
Biosynth
Langzeitlagerung:
Hinweise:

Chemische Eigenschaften

MDL:
Schmelzpunkt:
Siedepunkt:
Flammpunkt:
Dichte:
Konzentration:
EINECS:
Merck:
HS-Code:

Gefahrenhinweise

UN-Nummer:
EQ:
Klasse:
H-Sätze:
P-Sätze:
Flugverbot:
Gefahrenhinweis:
Verpackungsgruppe:
LQ:

Technische Anfrage zu: 3D-PP45352 Ac-VFAQ-OH

Bitte verwenden Sie stattdessen den Warenkorb, um ein Angebot oder eine Bestellung anzufordern

Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.

* Obligatorische felder
Willkommen bei CymitQuimica!Wir verwenden Cookies, um Ihren Besuch zu verbessern. Wir schließen Werbung nicht ein.

Bitte beachten Sie unsere Cookie-Richtlinie  für weitere Details oder passen Sie Ihre Einstellungen unter “Konfigurieren” an.